Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells or Circulating DNA in Adult Patients With Metastatic Cancer

Metastatic Cancer Clinical Trial

— Liquid Biopsy  

Official title:

Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells or Circulating DNA in Adult Patients With Metastatic Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02666612
• Other study ID #: 2008-A00585-50
• Secondary ID: 2008/1370
• Status: Recruiting
• Phase: N/A
• First received: August 12, 2015
• Last updated: January 25, 2017
• Start date: August 2008
• Est. completion date: August 2023

Study information

• Verified date: January 2017
• Source: Gustave Roussy, Cancer Campus, Grand Paris
• Contact: Jean Charles Soria, MD-PhD
• Phone: 0142114291
• Email: soria[@]gustaveroussy.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Monitoring of circulating endothelial cells (CEC and mature cells called progenitors called CEP) or circulating tumor cells (CTC) in adult patients with metastatic cancer, possibly treated with targeted therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2240
• Est. completion date: August 2023
• Est. primary completion date: August 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with metastatic solid tumor

• Age> 18 years

• Signed consent

Exclusion Criteria:

• Patients with diseases associated with vascular lesions known.

• Patients protected by law, in accordance with Articles L1121-5 to L1121-8 of the Code of Public Health.

• Mental pathology that can interfere with the proper conduct of the study.

• Refusal of consent.

Related Conditions & MeSH terms

• Metastatic Cancer
• Neoplasm Metastasis
• Neoplasms
• Neoplasms, Second Primary
• Neoplastic Cells, Circulating

Intervention

Procedure:
• Blood samples

Locations

Country	Name	City	State
France	Gustave Roussy Cancer Campus Grand Paris	Villejuif	Val de Marne

Sponsors (1)

Lead Sponsor	Collaborator
Gustave Roussy, Cancer Campus, Grand Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement and characterization of CEC and CEP and circulaing DNA rate using flow cytometry	Measurement and characterization of initial CEC and CEP circulaing DNA and their evolution under treatment	up to 2 years